EP4069244A4 - USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS - Google Patents

USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS Download PDF

Info

Publication number
EP4069244A4
EP4069244A4 EP20895126.9A EP20895126A EP4069244A4 EP 4069244 A4 EP4069244 A4 EP 4069244A4 EP 20895126 A EP20895126 A EP 20895126A EP 4069244 A4 EP4069244 A4 EP 4069244A4
Authority
EP
European Patent Office
Prior art keywords
reboxetine
nervous system
system disorders
treat nervous
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20895126.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4069244A1 (en
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/740,329 external-priority patent/US20200147093A1/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Priority claimed from PCT/US2020/062560 external-priority patent/WO2021113163A1/en
Publication of EP4069244A1 publication Critical patent/EP4069244A1/en
Publication of EP4069244A4 publication Critical patent/EP4069244A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20895126.9A 2019-12-03 2020-11-30 USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS Pending EP4069244A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962943077P 2019-12-03 2019-12-03
US201962946295P 2019-12-10 2019-12-10
US16/740,329 US20200147093A1 (en) 2018-10-15 2020-01-10 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,410 US20200147095A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,409 US11351175B2 (en) 2018-10-15 2020-01-11 Use of reboxetine to treat narcolepsy
US16/740,411 US20200147096A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
PCT/US2020/062560 WO2021113163A1 (en) 2019-12-03 2020-11-30 Use of reboxetine to treat nervous system disorders

Publications (2)

Publication Number Publication Date
EP4069244A1 EP4069244A1 (en) 2022-10-12
EP4069244A4 true EP4069244A4 (en) 2023-12-20

Family

ID=81851750

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20895126.9A Pending EP4069244A4 (en) 2019-12-03 2020-11-30 USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS

Country Status (12)

Country Link
EP (1) EP4069244A4 (ko)
JP (1) JP2023504685A (ko)
KR (1) KR20220108122A (ko)
CN (1) CN114746097A (ko)
AU (1) AU2020395082A1 (ko)
BR (1) BR112022010677A2 (ko)
CA (1) CA3163505A1 (ko)
CO (1) CO2022007507A2 (ko)
CR (1) CR20220247A (ko)
IL (1) IL293536A (ko)
MX (1) MX2022006630A (ko)
PE (1) PE20230181A1 (ko)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60035232T2 (de) * 1999-07-01 2008-02-14 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
PL197981B1 (pl) * 1999-07-01 2008-05-30 Upjohn Co Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
NZ581707A (en) * 2007-05-07 2011-05-27 Chelsea Therapeutics Inc Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
DK2968208T3 (da) * 2013-03-13 2022-08-22 Jazz Pharmaceuticals Ireland Ltd Behandling af kataplexi

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GARCIA-BORREGUERO D ET AL: "567.K Effects of reboxetine in narcolepsy-cataplexy: Preliminary findings on 14 patients", SLEEP; 15TH ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES; CHICAGO, ILLINOIS, USA; JUNE 05-10, 2001, ALLEN PRESS, LAWRENCE, KS, US, vol. 24, no. Abstract Supplement, 15 April 2001 (2001-04-15), pages A323 - A324, XP009531711, ISSN: 0161-8105 *
O' GORMAN CEDRIC ET AL: "SCIENTIFIC RATIONALE AND CLINICAL DEVELOPMENT OF AXS-12 FOR NARCOLEPSY", SLEEP, vol. 42, no. Abstract Supplement, 1 January 2019 (2019-01-01), pages A24, XP055866024 *
SCHMIDT CHRISTIAN ET AL: "The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram", BEHAVIOURAL BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 308, 23 April 2016 (2016-04-23), pages 205 - 210, XP029542431, ISSN: 0166-4328, DOI: 10.1016/J.BBR.2016.04.033 *
See also references of WO2021113163A1 *

Also Published As

Publication number Publication date
CN114746097A (zh) 2022-07-12
IL293536A (en) 2022-08-01
CA3163505A1 (en) 2021-06-10
JP2023504685A (ja) 2023-02-06
PE20230181A1 (es) 2023-02-01
AU2020395082A1 (en) 2022-06-09
KR20220108122A (ko) 2022-08-02
EP4069244A1 (en) 2022-10-12
BR112022010677A2 (pt) 2022-08-16
CO2022007507A2 (es) 2022-06-21
MX2022006630A (es) 2022-06-24
CR20220247A (es) 2022-08-18

Similar Documents

Publication Publication Date Title
EP4010072A4 (en) TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
EP3526319A4 (en) METHOD AND COMPOSITIONS AND FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL VENTILATION SYSTEM
EP3259017A4 (en) Nerve stimulation for treatment of diseases and disorders
EP3389725A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP3618824A4 (en) USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP3429605A4 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES, IN PARTICULAR DISEASES AFFECTING THE CENTRAL NERVOUS SYSTEM
EP3596063A4 (en) PYRIMIDINYL PYRIDYLOXY NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1 RELATED DISEASES AND DISORDERS
EP3579830A4 (en) Fatty acid formulations containing cannabis for the treatment of diseases of the nervous system
EP3507371A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM
EP3700525A4 (en) IMPROVED PROVISION OF ANTIOXIDANTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH OXIDATIVE STRESS
EP3270914A4 (en) Compounds and forms of treatment for female sexual disorders
EP3826650A4 (en) METHODS OF TREATMENT OF NEUROLOGICAL DISEASES
EP3914231A4 (en) TREATMENT OF SKIN DISEASES WITH TOPICAL TAPINAROF COMBINATION COMPOSITIONS
CA3082254A1 (en) Heterocyclic compounds as kinase inhibitors
EP3856169A4 (en) Methods of treating myeloproliferative disorders
EP3826649A4 (en) METHODS OF TREATMENT OF NEUROLOGICAL DISORDERS
EP4069847A4 (en) TREATMENT OF LOWER RESPIRATORY DISEASES
IL283503A (en) Combined treatment of primary central nervous system lymphoma
EP3634370A4 (en) TREATMENT OF SKIN DISEASES
EP3927428A4 (en) METHODS OF TREATMENT OF RESPIRATORY CONDITIONS
EP3911313A4 (en) THIENYL ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN DISEASES
GB201914034D0 (en) Treatment of neurological disorders
EP3856198A4 (en) TREATMENT OF LOW INTENSITY HEMATOLOGICAL DISORDERS
EP3866768A4 (en) USING REBOXETINE TO TREAT NARCOLEPSY
EP3709982A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS AND SKIN DISEASES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080135

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

A4 Supplementary search report drawn up and despatched

Effective date: 20231122

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20231116BHEP

Ipc: A61P 25/00 20060101ALI20231116BHEP

Ipc: A61P 25/24 20060101ALI20231116BHEP

Ipc: A61K 31/5375 20060101AFI20231116BHEP